DZ-837
DZ-837 (compound 3d) is a PROTAC targeting BCL6 with a DC50 of approximately 600 nM. DZ-837 can induce cell cycle arrest and exert synergistic anticancer effects with Ibrutinib. DZ-837 is composed of PROTAC target protein ligand BCL6 ligand-2 (HY-161990) (red part), E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), and PROTAC Linker (HY-W245803) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is 2- (2,6-Dioxopiperidin-3-yl) -4- ((2- (2-hydroxyethoxy) ethyl) amino) isoindoline-1,3-dione (HY-W924949).
Product Specifications
UNSPSC
12352005
Target
BCL6; PROTACs
Type
Reference compound
Related Pathways
Immunology/Inflammation; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dz-837.html
Purity
96.04
Solubility
DMSO : 25 mg/mL (ultrasonic; heat to 60°C)
Smiles
O=C(C1=CC=C(C2=CCCC2)S1)NC3=CC=C(NC4=NC(N5CCN(CCOCCNC6=CC=CC(C(N7C(CC8)C(NC8=O)=O)=O)=C6C7=O)CC5)=NC=C4F)C=C3OC
Molecular Formula
C42H44FN9O7S
Molecular Weight
837.92
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Putative POU domain, class 5, transcription factor 1B (POU5F1B) ELISA Kit
Tfap2a CRISPR All-in-one AAV vector set (with saCas9)(Human)
